



Anders H. Kverneland, MD, PhD, is joining BRIDGE as he has been appointed a BRIDGE fellowship for the coming 2 years. Here he will focus his research into the side effects to immune therapy at the molecular level. The potency of immune therapy is well known and every year new types of cancer patients are treated with immune therapy. Less is known about the side effects of immune therapy although they can be equally potent, but research into this area is close to absent. Examples include serious conditions such as inflammation of the intestine, liver or lung, and chronic endocrine disorders secondary to immune-mediated destruction of healthy hormone glands. Specifically, Anders will focus on changes to the blood proteome during an immune therapy mediated side effects to help guide future clinical decision-making and general management of this growing problem.

Anders' BRIDGE mentor team consists of Inge Marie Svane, clinical professor and director of the National Center for Cancer Immune Therapy (CCIT-DK) and Jesper Velgaard Olsen, professor and deputy director of the Novo Nordisk Foundation Center for Protein Research.